Quantcast
Home > Quotes > CBIO
CBIO

Catalyst Biosciences, Inc. Common Stock (CBIO) Quote & Summary Data

$6.81
*  
0.23
3.27%
Get CBIO Alerts
*Delayed - data as of Aug. 23, 2019  -  Find a broker to begin trading CBIO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
29.5
Today's High / Low
$ 7.15 / $ 6.75
Share Volume
42,118
50 Day Avg. Daily Volume
204,740
Previous Close
$ 7.04
52 Week High / Low
$ 11.4448 / $ 6.20
Market Cap
81,828,422
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.82

Intraday Chart

Shares Traded

Share Volume:
42,118
50 Day Avg. Daily Volume:
204,740

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.96

Trading Range

The current last sale of $6.81 is 9.84% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 7.15 $ 11.4448
 Low: $ 6.75 $ 6.20

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on developing novel medicines to address serious medical conditions for individuals who need new or better treatment options. We are focusing our product development efforts in the field of hemostasis (the process that regulates bleeding) and have a mission to develop valuable therapies for individuals with hemophilia. We used a scientific approach to engineer several protease-based therapeutic candidates that regulate blood clotting. Our most advanced program, a subcutaneously administered, next-generation engineered coagulation Factor VIIa, marzeptacog alfa (activated) ("MarzAA"), has completed enrollment of the Phase 2 portion of a Phase 2/3 subcutaneous dosing trial in individuals with hemophilia with an inhibitor.  ... More ...  



Risk Grade

Where does CBIO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 7.02
Open Date:
Aug. 23, 2019
Close Price:
$ 6.81
Close Date:
Aug. 23, 2019


Consensus Recommendation

Analyst Info